The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events.
Martin Henner Voss
No relevant relationships to disclose
Diogo Assed Bastos
No relevant relationships to disclose
Christoph Karlo
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Albulena Ajeti
No relevant relationships to disclose
A. Ari Hakimi
No relevant relationships to disclose
Darren Richard Feldman
Consultant or Advisory Role - Novartis; Novartis
Ana M. Molina
Research Funding - Novartis
Michael F. Berger
No relevant relationships to disclose
James Hsieh
Research Funding - Novartis; Novartis; Pfizer; Pfizer
Robert John Motzer
Consultant or Advisory Role - Pfizer; Pfizer
Research Funding - Novartis; Novartis; Pfizer; Pfizer